SGLT2 Inhibitors and HFpEF: A Promise Fulfilled?
Published: 05 October 2022
20m 45sPart 6 Q&A and Panel Discussion
This broadcast 'SGLT2 Inhibitors and HFpEF: A Promise Fulfilled?' looks at the latest results from clinical trials studying pharmacotherapies in people with HFpEF, and current and emerging approaches in HFpEF diagnosis.
Dr Shelley Zieroth (St Boniface Hospital, CA) moderates proceedings, and is joined by an outstanding faculty, Prof Carolyn Lam (National Heart Centre, SG), Prof John McMurray (University of Glasgow, UK) Dr Scott Solomon (Brigham and Women's Hospital, US), and Dr Subodh Verma (St. Michael's Hospital, Toronto, CA), for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
- To outline current and emerging approaches in HFpEF diagnosis
- To describe the latest results from clinical trials studying pharmacotherapies in people with HFpEF
- To explain how to practically personalise HFpEF management with established and novel drugs
- Primary Care Physicians
- Diabetes Educators
More from this programme
HFpEF: Unraveling the Mysteries of a Recalcitrant Medical Problem
SGLT2i in the Treatment of HFpEF: Have They Delivered in Clinical Trials?
From DAPA-HF to DELIVER: Does Ejection Fraction Really Matter?
From Paper to Practice - Practical Tips for Physicians
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Professor and Senior Consultant
Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.
Director, Noninvasive Cardiology / Professor
Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. His research group has played a leading role in clinical trials in heart failure, hypertension and myocardial infarction.
He received his AB from Williams College and his MD from Harvard Medical School.
John JV McMurray
Professor of Cardiology
Prof John McMurray is Professor of Medical Cardiology and Deputy Director of the Institute of Cardiovascular and Medical Sciences at the University of Glasgow, and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow. A graduate of Manchester University, Prof McMurray completed postgraduate research at the University of Dundee.
Prof McMurray is a Fellow of the European Society of Cardiology (ESC), American College of Cardiology and American Heart Association as well as the medical Royal Colleges in Edinburgh and Glasgow and the Royal Society of Edinburgh and UK Academy of Medical Sciences.
Dr Subodh Verma is a cardiac surgeon-scientist at St Michael’s Hospital and Professor in the Departments of Surgery, and Pharmacology and Toxicity at the University of Toronto. He is also the current Canada Research Chair in Cardiovascular Surgery.
Dr Verma oversees a prolific basic, translational and clinical research program. He spearheads the CARDIOLINK clinical trials platform at St Michael’s Hospital and has leadership roles in seven ongoing global heart failure trials.